Tempus introduces xm, an assay to monitor immunotherapy response for patients with advanced cancers

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced xm for treatment response monitoring (trm), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ici) therapy in advanced solid tumors. xm for trm is the newest addition to tempus' growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (mrd). it.
TEM Ratings Summary
TEM Quant Ranking